Cross-Species Upregulation of MAGED2 in Liver Cancer Suggests a Role in Obesity-Driven Tumor Progression

TL;DR

A gene called MAGED2 is found to be more active in liver cancer in both humans and mice, suggesting it plays a role in obesity-related tumor growth.

Contribution

MAGED2 is identified as a conserved marker of liver cancer across species, revealing insights into obesity-driven tumor progression.

Findings

MAGED2 is significantly upregulated in mouse liver tumors and human HCC samples.

MAGED2 upregulation is associated with patient prognosis in human HCC.

Type I MAGE genes are not expressed in mouse liver tumors, indicating species-specific regulation.

Abstract

Melanoma-associated antigens (MAGEs) are cancer-testis antigens (CTAs) aberrantly expressed in multiple cancer types, including hepatocellular carcinoma (HCC), and associated with aggressive phenotypes. Although MAGE proteins are widely studied as cancer immunotherapy targets, their roles in HCC and the regulation of their expression during liver pathogenesis in mouse models, including dietary effects, remain poorly understood. We analyzed Mage gene expression in liver tissues from 78 C3H/HeJ mice with chronic diet-induced obesity. While type I MAGE genes are frequently expressed in human HCC, we found no evidence of their expression in mouse liver tumors, suggesting species-specific regulation. In contrast, type II Maged2, previously reported to be upregulated in human HCC, was significantly increased in mouse liver tumors. Analysis of human HCC samples from The Cancer Genome Atlas (TCGA) database confirmed MAGED2 upregulation and its association with patient prognosis. Together, these findings identify MAGED2 as a conserved marker of liver cancer in both humans and mice and emphasize the importance of cross-species comparative approaches for selecting appropriate models and accurately interpreting results, particularly for CTAs, which often evolved recently and in a species-specific manner.

Figures